Swedish DPI developer Iconovo has announced a manufacturing, sales, and distribution agreement with Stevanato Group for its ICOcap dry powder inhaler.
The capsule-based ICOcap device will be manufactured by Stevanato Group subsidiary Balda. According to the announcement, Stevanato Group has a sales and marketing presence in more than 150 countries.
Iconovo CEO Orest Lastow commented, “This is a very important deal for us because ICOcap will now be directly available as an off-the-shelf product to all our customers who prefer not to manufacture inhalers themselves. Stevanato Group is an ideal partner for us as it has the capabilities to manufacture the device.”
Stevanato Group CEO Franco Stevanato said, ”We’re extremely pleased for this cooperation and licensing agreement with an innovative company such as Iconovo. It extends our product portfolio in the drug delivery systems field, particularly in the respiratory for asthma and COPD (Chronic Obstructive Pulmonary Disease). ICOcap is the result of a broad experience in inhalers and represents the first step of a collaboration which we hope could possibly extend to other products. By bringing in our extended commercial network and our global production footprint we can provide a system solution to pharmaceutical customers, close to their manufacturing sites.”
Within the past year, Iconovo has announced development deals for its ICOone unit dose DPI and for its ICOres reservoir based DPI.
Read the Iconovo press release.
